Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gevokizumab Safety Extension in Pyoderma Gangrenosum
NCT02318914Phase 3Terminated
- Sponsor
- XOMA
- Start
- Nov 2014
- Primary completion
- Feb 2016
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of gevokizumab in pyoderma gangrenosum (PG), sponsored by XOMA. Primary endpoints: Evaluation of treatment-emergent adverse events up to 2 years, Changes from baseline vital signs, physical examination results, and laboratory test results up to 2 years and 1 more. Started Nov 2014; status: terminated.
02
Drugs
gevokizumab
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT02318914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02318914.